Semaglutide
GLP-1 receptor agonist for weight loss
Overview
Semaglutide is a long-acting GLP-1 receptor agonist that has transformed the landscape of obesity treatment. Originally developed for type 2 diabetes, it has shown remarkable efficacy for weight loss and cardiovascular risk reduction.
Mechanism of Action
Selective GLP-1 receptor agonist → mimics natural GLP-1 → stimulates insulin secretion → suppresses appetite via hypothalamic signaling → slows gastric emptying → 94% homology to human GLP-1.
Benefits
- ~15-17% body weight loss
- Cardiovascular risk reduction
- Improved glycemic control
- Once-weekly dosing
- FDA-approved for obesity
Dosing Protocol
Half-Life
~7 days
Duration of pharmacological activity after administration.
Side Effects
- Nausea (most common)
- Vomiting
- Diarrhea
- Constipation
- Pancreatitis (rare)
- Thyroid concerns (boxed warning)
Stacking Recommendations
Storage & Reconstitution
Refrigerate at 2–8°C. In-use pen: room temperature up to 56 days.
Research Notes
FDA-approved as Wegovy (obesity) and Ozempic (T2DM). STEP trials demonstrated 15-17% weight loss. SELECT trial proved cardiovascular benefit. Oral formulation (Rybelsus) available.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.